Tags

Type your tag names separated by a space and hit enter

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.

Abstract

BACKGROUND

Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist, administered alone or concomitantly with loratadine, an H(1)-receptor antagonist, in seasonal allergic rhinitis.

OBJECTIVE

The purpose of this study was to determine the effect of concomitant use of montelukast and loratadine in the treatment of seasonal allergic rhinitis.

METHODS

In this multicenter (N = 12) double-blind, randomized, parallel-group, placebo-controlled 2-week trial, 460 men and women, aged 15 to 75 years, with spring seasonal allergic rhinitis were randomly allocated to receive 1 of the following 5 treatments: montelukast 10 or 20 mg, loratadine 10 mg, montelukast 10 mg with loratadine 10 mg, or placebo, once daily in the evening. The primary end point was daytime nasal symptoms score (average of congestion, rhinorrhea, itching, and sneezing). Other end points were eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations (patient's and physician's), and rhinoconjunctivitis quality-of-life scores.

RESULTS

Concomitant montelukast with loratadine improved the primary end point significantly (P <.001) compared with placebo and each agent alone. Compared with placebo, montelukast with loratadine also significantly improved eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations, and quality of life. Montelukast alone and loratadine alone caused modest improvements in rhinitis end points. All treatments were similarly well tolerated.

CONCLUSIONS

Concomitant montelukast with loratadine provided effective treatment for seasonal allergic rhinitis and associated eye symptoms with a safety profile comparable with placebo.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA.

    , , , , , ,

    Source

    MeSH

    Acetates
    Adolescent
    Adult
    Aged
    Anti-Allergic Agents
    Drug Therapy, Combination
    Female
    Humans
    Leukotriene Antagonists
    Loratadine
    Male
    Middle Aged
    Placebos
    Quinolines
    Rhinitis, Allergic, Seasonal
    Time Factors

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    10808172

    Citation

    Meltzer, E O., et al. "Concomitant Montelukast and Loratadine as Treatment for Seasonal Allergic Rhinitis: a Randomized, Placebo-controlled Clinical Trial." The Journal of Allergy and Clinical Immunology, vol. 105, no. 5, 2000, pp. 917-22.
    Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5):917-22.
    Meltzer, E. O., Malmstrom, K., Lu, S., Prenner, B. M., Wei, L. X., Weinstein, S. F., ... Reiss, T. F. (2000). Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. The Journal of Allergy and Clinical Immunology, 105(5), pp. 917-22.
    Meltzer EO, et al. Concomitant Montelukast and Loratadine as Treatment for Seasonal Allergic Rhinitis: a Randomized, Placebo-controlled Clinical Trial. J Allergy Clin Immunol. 2000;105(5):917-22. PubMed PMID: 10808172.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. AU - Meltzer,E O, AU - Malmstrom,K, AU - Lu,S, AU - Prenner,B M, AU - Wei,L X, AU - Weinstein,S F, AU - Wolfe,J D, AU - Reiss,T F, PY - 2000/5/16/pubmed PY - 2000/6/10/medline PY - 2000/5/16/entrez SP - 917 EP - 22 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 105 IS - 5 N2 - BACKGROUND: Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist, administered alone or concomitantly with loratadine, an H(1)-receptor antagonist, in seasonal allergic rhinitis. OBJECTIVE: The purpose of this study was to determine the effect of concomitant use of montelukast and loratadine in the treatment of seasonal allergic rhinitis. METHODS: In this multicenter (N = 12) double-blind, randomized, parallel-group, placebo-controlled 2-week trial, 460 men and women, aged 15 to 75 years, with spring seasonal allergic rhinitis were randomly allocated to receive 1 of the following 5 treatments: montelukast 10 or 20 mg, loratadine 10 mg, montelukast 10 mg with loratadine 10 mg, or placebo, once daily in the evening. The primary end point was daytime nasal symptoms score (average of congestion, rhinorrhea, itching, and sneezing). Other end points were eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations (patient's and physician's), and rhinoconjunctivitis quality-of-life scores. RESULTS: Concomitant montelukast with loratadine improved the primary end point significantly (P <.001) compared with placebo and each agent alone. Compared with placebo, montelukast with loratadine also significantly improved eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations, and quality of life. Montelukast alone and loratadine alone caused modest improvements in rhinitis end points. All treatments were similarly well tolerated. CONCLUSIONS: Concomitant montelukast with loratadine provided effective treatment for seasonal allergic rhinitis and associated eye symptoms with a safety profile comparable with placebo. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/10808172/Concomitant_montelukast_and_loratadine_as_treatment_for_seasonal_allergic_rhinitis:_a_randomized_placebo_controlled_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(00)80014-7 DB - PRIME DP - Unbound Medicine ER -